Core Viewpoint - Rosen Law Firm has initiated a class action lawsuit against Atara Biotherapeutics, Inc. (NASDAQ: ATRA) on behalf of investors who purchased securities between May 20, 2024, and January 9, 2026, alleging that the company misled investors regarding its business operations and regulatory prospects [1][2]. Group 1: Allegations and Lawsuit Details - The lawsuit claims that Atara Biotherapeutics made false and misleading statements about its manufacturing issues and the regulatory prospects of its tabelecleucel Biologics License Application (BLA), which were overstated [2]. - Specific allegations include that manufacturing deficiencies and issues with the ALLELE study made FDA approval unlikely, and these problems heightened regulatory scrutiny and jeopardized ongoing clinical trials [2]. - The lawsuit asserts that these misrepresentations had a significant negative impact on Atara's business and financial condition, leading to investor damages when the truth was revealed [2]. Group 2: Participation and Legal Representation - Shareholders wishing to act as lead plaintiffs in the class action must file motions with the court by May 22, 2026, and do not need to participate in the case to be eligible for recovery [2]. - Rosen Law Firm operates on a contingency fee basis, meaning shareholders will not incur any fees or expenses unless they recover losses [3].